Stocktoria
Aurobindo Pharma Limited AUROPHARMA.NS
Aurobindo Pharma Limited (AUROPHARMA.NS) earns a Piotroski F-score of 6/9 (mixed financial health). It pays a dividend yielding 0.26% (safety: safe). FY2026 revenue was ₹333.8B at a 10.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Healthcare · percentile among 80 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
FAQ
Is AUROPHARMA.NS financially healthy?
Aurobindo Pharma Limited's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak).
Does AUROPHARMA.NS pay a dividend, and is it safe?
Yes. Aurobindo Pharma Limited pays a dividend yielding about 0.26% with a 6.6% payout ratio, rated “safe” for safety.
How profitable is AUROPHARMA.NS?
In FY2026, Aurobindo Pharma Limited had a net margin of 10.5% and a return on equity of 9.2%.
What is AUROPHARMA.NS's P/E ratio?
Aurobindo Pharma Limited's trailing price-to-earnings (P/E) ratio is about 25.8×, based on its latest annual earnings.
What is the analyst price target for AUROPHARMA.NS?
The average Wall-Street price target for Aurobindo Pharma Limited is ₹1,564.79, about 0.5% below the recent price, from 29 analysts (consensus: buy).
Is AUROPHARMA.NS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Aurobindo Pharma Limited: a Piotroski F-score of 6/9, a P/E of about 25.8×, a dividend yield of 0.26%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · IN · as of 2026-03-31. Figures in INR. Facts plus Stocktoria's own computed scores — not investment advice.